» Articles » PMID: 32869516

Race Modifies Survival Benefit of Guideline-based Treatment: Implications for Reducing Disparities in Muscle Invasive Bladder Cancer

Overview
Journal Cancer Med
Specialty Oncology
Date 2020 Sep 2
PMID 32869516
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Black individuals with muscle-invasive bladder cancer (MIBC) experienced 21% lower odds of guideline-based treatment (GBT) and differences in treatment explain 35% of observed Black-White differences in survival. Yet little is known of how interactions between race/ethnicity and receipt of GBT drive within- and between-race survival differences.

Methods: Black, White, and Latino individuals diagnosed with nonmetastatic, locally advanced MIBC from 2004 to 2013 within the National Cancer Database were included. Guideline-based treatment was defined as the receipt including one or more of the following treatment modalities: radical cystectomy (RC), neoadjuvant chemotherapy with RC, RC with adjuvant chemotherapy, and/or chemoradiation based on American Urological Association guidelines. Cox proportional hazards model of mortality estimated effects of GBT status, race/ethnicity, and the GBT-by-race/ethnicity interaction, adjusting for covariates.

Results: Of the 54 910 MIBC individuals with 125 821 person-years of posttreatment observation (max = 11 years), 6.9% were Black, and 3.0% were Latino. Overall, 51.4%, 45.3%, and 48.5% of White, Black, and Latino individuals received GBT. Latino individuals had lower hazard of death compared to Black (HR 0.81, 95% CI 0.75-0.87) and White individuals (HR 0.92, 95% 0.86-0.98). With GBT, Latino and White individuals had similar outcomes (HR = 1.00, 95% 0.91-1.10) and both fared better than Black individuals (HR = 0.88, 95% 0.79-0.99 and HR = 0.88, 95% 0.83-0.94, respectively). Without GBT, Latino individuals fared better than White (HR = 0.85, 95% 0.77-0.93) and Black individuals (HR = 0.74, 95% 0.67-0.82) while White individuals fared better than Black individuals (HR = 0.87, 95% 0.83-0.92). Black individuals with GBT fared worse than Latinos without GBT (HR = 1.02, 95% 0.92-1.14), although not statistically significant.

Conclusion: Low GBT levels demonstrated an "under-allocation" of GBT to those who needed it most-Black individuals. Interventions to improve GBT allocation may mitigate race-based survival differences observed in MIBC.

Citing Articles

Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.

Ladi-Seyedian S, Ghoreifi A, Konety B, Pohar K, Holzbeierlein J, Taylor J Cancers (Basel). 2024; 16(7).

PMID: 38610946 PMC: 11011163. DOI: 10.3390/cancers16071268.


Approaches to developing de novo cancer population models to examine questions about cancer and race in bladder, gastric, and endometrial cancer and multiple myeloma: the Cancer Intervention and Surveillance Modeling Network incubator program.

Sereda Y, Alarid-Escudero F, Bickell N, Chang S, Colditz G, Hur C J Natl Cancer Inst Monogr. 2023; 2023(62):219-230.

PMID: 37947329 PMC: 11009510. DOI: 10.1093/jncimonographs/lgad021.


Race modifies survival benefit of guideline-based treatment: Implications for reducing disparities in muscle invasive bladder cancer.

Washington 3rd S, Gregorich S, Meng M, Suskind A, Porten S Cancer Med. 2020; 9(22):8310-8317.

PMID: 32869516 PMC: 7666728. DOI: 10.1002/cam4.3429.

References
1.
Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

2.
Washington 3rd S, Gregorich S, Meng M, Suskind A, Porten S . Race modifies survival benefit of guideline-based treatment: Implications for reducing disparities in muscle invasive bladder cancer. Cancer Med. 2020; 9(22):8310-8317. PMC: 7666728. DOI: 10.1002/cam4.3429. View

3.
Rocque G, Williams C, Miller H, Azuero A, Wheeler S, Pisu M . Impact of Travel Time on Health Care Costs and Resource Use by Phase of Care for Older Patients With Cancer. J Clin Oncol. 2019; 37(22):1935-1945. PMC: 6804875. DOI: 10.1200/JCO.19.00175. View

4.
DeSantis C, Miller K, Sauer A, Jemal A, Siegel R . Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019; 69(3):211-233. DOI: 10.3322/caac.21555. View

5.
Westergren D, Gardmark T, Lindhagen L, Chau A, Malmstrom P . A Nationwide, Population Based Analysis of Patients with Organ Confined, Muscle Invasive Bladder Cancer Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014. J Urol. 2019; 202(5):905-912. DOI: 10.1097/JU.0000000000000350. View